Villere ST Denis J & Co. LLC Raises Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Villere ST Denis J & Co. LLC increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 62,442 shares of the company’s stock after acquiring an additional 1,556 shares during the quarter. IDEXX Laboratories makes up about 2.3% of Villere ST Denis J & Co. LLC’s portfolio, making the stock its 23rd biggest holding. Villere ST Denis J & Co. LLC’s holdings in IDEXX Laboratories were worth $25,816,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IDXX. FSA Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories during the third quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after buying an additional 57 shares in the last quarter. Retirement Wealth Solutions LLC purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth $31,000. Mowery & Schoenfeld Wealth Management LLC grew its holdings in shares of IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after buying an additional 60 shares in the last quarter. Finally, Ashton Thomas Securities LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter valued at about $37,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on IDXX. Piper Sandler boosted their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Barclays upped their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $533.75.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,330 shares of company stock worth $6,161,276. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Down 3.3 %

IDXX stock opened at $444.53 on Friday. The company’s 50 day moving average price is $430.77 and its 200 day moving average price is $453.31. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.03 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39. The firm has a market capitalization of $36.40 billion, a price-to-earnings ratio of 41.66, a PEG ratio of 3.47 and a beta of 1.37.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.